Navigation Links
Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
Date:5/20/2009

BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding planned publications of results from clinical trials with blinatumomab and adecatumumab, the efficacy, safety and intended utilization of our pro
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Technology Applications International ... that its wholly-owned subsidiary Renuell Int,l, Inc. has signed ... and Space Administration ("NASA") at the Johnson Space Center ... See photos: tapplic.com/houstonphotos/ ... are very pleased to announce our latest, exclusive agreement ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ... M.D., President and Chief Executive Officer, will present at the ... in New York on Tuesday, Sept. ... live and archived webcast of the presentation will be accessible ... "News & Events" section. About Oncothyreon ...
(Date:9/2/2014)... Culot brings life science and ... services  BioData, producer of Labguru, the web-based ... the appointment of Louis Culot as the ... Marketing and Business Development at BioDiscovery Inc., developer of ... Previously, Culot worked for 17 years with ...
(Date:8/31/2014)... , Aug. 31, 2014 Wockhardt Limited today ... program in Anti-Infective research when two of its drugs, ... Infectious Disease Product (QIDP) status from U.S. Food & ... which act against pathogens which have a high degree ... by Centre for Disease Control (a top U.S. government ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Louis Culot Appointed as BioData's CEO 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3
... advanced tools after their brains evolved a greater capacity for ... it took early humans almost two million years to move ... used computer modelling and tiny sensors embedded in gloves to ... order to make two types of tools during the Lower ...
... 2010Scientists at the U.S. Department of Energy,s Los Alamos ... thin films capable of absorbing light and generating electric ... in the journal Chemistry of Materials, could ... "Potentially, with future refinement of this technology, windows in ...
... Colo., Nov. 3, 2010 Bolder BioTechnology, Inc. today ... $1.2 million in Qualifying Therapeutic Discovery Project Grants.  Grants ... Discovery Project Tax Credit Program, which authorized up to ... companies with 250 or fewer employees.   ...
Cached Biology Technology:Stone Age humans needed more brain power to make big leap in tool design 2Scientists produce transparent, light-harvesting material 2Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants 2
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
(Date:9/2/2014)... people take stress in stride; others are done in ... the molecular mechanisms of this so-called stress gap in ... that could lead researchers to better understand the development ... "Like people, each animal has unique experiences as it ... life experiences can alter the expression of genes, and ...
(Date:9/1/2014)... ─ Dietary quality in the U.S. has improved steadily ... fat intakebut overall dietary quality remains poor and disparities ... to a new study from Harvard School of Public ... evidence to date that the extensive efforts by many ... having some payoff, but it also indicates that these ...
Breaking Biology News(10 mins):Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3
... British Columbia researchers are part of an international team ... a step they hope will lead to a universal ... conservation efforts. Barcodes based on portions of DNA ... have already emerged as a viable solution for ...
... The most comprehensive analysis yet of the genome of childhood ... the genetic blueprint, suggesting the cancer arises from just a ... Children,s Research Hospital. The research appears in the July 27 ... of Sciences . "Our data raise the ...
... BOSTONThe androgen receptor a protein ignition switch ... a master of adaptability. When drug therapy deprives the ... receptor manages to find an alternate growth route. A ... University scientists demonstrates how. The shift from androgen-dependent to ...
Cached Biology News:UBC researchers help push for standard DNA barcodes for plants 2Comprehensive look at rare leukemia finds relatively few genetic changes launch disease 2Comprehensive look at rare leukemia finds relatively few genetic changes launch disease 3Study reveals a reprogrammed role for the androgen receptor 2
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
...
ANTI GELSOLIN...
... Supply, 1. 3500 V, 400 mA, 200 ... and linear voltage ramp modes.Linear voltage ramp ... IPG strips quickly without danger of overheating.Volt-hour ... gel thickness, sample ionic strength, and temperature.Stores ...
Biology Products: